Taylor & Francis
Taylor & Francis Group

Expert Opinion on Therapeutic Patents

ISSN: 1354-3776 (Print) 1744-7674 (Online) Journal homepage: informahealthcare.com/journals/ietp20

Response to Deng *et al.*'s LRRK2 patent review

Daniel Jon Burdick

To cite this article: Daniel Jon Burdick (2013) Response to Deng *et al.*'s LRRK2 patent review, Expert Opinion on Therapeutic Patents, 23:2, 279-279, DOI: 10.1517/13543776.2013.757594

To link to this article: https://doi.org/10.1517/13543776.2013.757594

EXPERT OPINION

Response to Deng *et al.*'s LRRK2 patent review

Daniel Jon Burdick
Genentech, Inc., Discovery Chemistry, South San Francisco, USA

Keywords: kinase, LRRK2, parkinson's disease, small molecule

Expert Opin. Ther. Patents (2013) ***23****(2):279-279*

In response to a recent article that was posted online on November 6, 2012 entitled "Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 – 2011)" (doi:10.1517/13543776.2012.729041).

The authors appear to claim that they were the first to discover compound **11** and that Genentech/Roche discovered **11** in a parallel effort. However, the patent and non-patent literature clearly shows that Genentech/Roche was the first to discover compound **11** and that the Gray group found it later.

On page 4 of the article, the authors present a misleading chronology of the discovery and reporting of compound **11**. The Genentech/Roche patent [1] (Reference 48 in this patent review) was published in December of 2011 and clearly exemplifies compound **11** as Example **3**. Because the compound was made before the provisional filing date of June 4, 2010, this clearly shows that this patent was the first disclosure of compound **11**.

The first disclosure of compound **11** in the non-patent literature was in the publication by Chen *et al.* [2] (Reference 50 in patent review). This article was received by *J. Med. Chem*. on March 31, 2012, and first published online on May 16, 2012. This publication appeared online six days before the publication by Choi *et al.* [3]. (Reference 47 in patent review) was received by *ACS Med. Chem. Lett*. (May 22, 2012). The Choi article was first published online on June 18, 2012.

Furthermore, the current article misrepresents the authorship of Reference 50 in the text as "Hu *et al.*" rather than the correct "Chen *et al.*" The authors also do not make reference anywhere in the text to compound **12** (Figure 6) as this compound has clearly been shown to have a superior LRRK2 activity and ADME profile in comparison to compound **11** [4].

Declaration of interest

The author of this letter is an employee of Genentech, Inc. The author declares no other conflict of interest and has received no payment in preparation of this correspondence.

Bibliography

1. Baker-Glenn C, Burdick D J, Chambers M, et al. Aminopyrimidine derivatives as LRRK2 modulators and their preparation and use for the treatment of Parkinson's disease. WO2011151360 A1 20111208; 2011
2. Chen H, Chan BK, Drummond J, et al. Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. J Med Chem 2012;55:5536-45
3. Choi HG, Zhang J, Deng X, et al. Brain penetrant LRRK2 inhibitor. ACS Med. Chem Lett 2012;3:658-62
4. Estrada AA, Liu X, Baker-Glenn C et al. Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem 2012; 55:9416-9433

Affiliation

Daniel Jon Burdick BS
Genentech, Inc., Discovery Chemistry, 1 DNA Way, South San Francisco, 94080, USA

informa
healthcare